Your account is not claimed yet. You can sign up with ORCID to claim your account.

Ataru Igarashi (A Igarashi)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 23

Top Venues

Journal of medical economics

BMJ open

Journal of market access & health policy

Expert review of vaccines

University of Tokyo

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Tokyo

Japan

Associate Professor :: Graduate School of Pharmaceutical Sciences

Publications

Ippei Morita, Kenji Kurazono, Manami Yoshida, Shinzo Hiroi, Kosuke Iwasaki, Tomomi Takeshima, Chise Ha, Ataru Igarashi
Preferences and values for government policies on infectious disease outbreaks and epidemics for the Japanese population: a conjoint analysis. Journal of medical economics (2023)
Miyuki Ezura, Katsuhiko Sawada, Yusuke Takushima, Ataru Igarashi, Lida Teng
A systematic review of the characteristics of data assessment tools to measure medical doctors' work-related quality of life. Journal of market access & health policy 11 (1) (2023)
Yoshiyuki Saito, Ataru Igarashi, Takeo Nakayama, Shingo Fukuma
Prevalence of multimorbidity and its associations with hospitalisation or death in Japan 2014-2019: a retrospective cohort study using nationwide medical claims data in the middle-aged generation. BMJ open 13 (5) (2023)
Yoshiyuki Saito, Ataru Igarashi, Takeo Nakayama, Shingo Fukuma
Prevalence of multimorbidity and its associations with hospitalisation or death in Japan 2014-2019: a retrospective cohort study using nationwide medical claims data in the middle-aged generation. BMJ open 13 (5) (2023)
Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, Yusuke Kajimoto, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Sumito Saeki, null null
Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives. Breast cancer (Tokyo, Japan) (2023)
Yoshiyuki Saito, Ataru Igarashi, Takeo Nakayama, Shingo Fukuma
Prevalence of multimorbidity and its associations with hospitalisation or death in Japan 2014-2019: a retrospective cohort study using nationwide medical claims data in the middle-aged generation. BMJ open 13 (5) (2023)
Yoshiyuki Saito, Ataru Igarashi, Takeo Nakayama, Shingo Fukuma
Prevalence of multimorbidity and its associations with hospitalisation or death in Japan 2014-2019: a retrospective cohort study using nationwide medical claims data in the middle-aged generation. BMJ open 13 (5) (2023)
Sumito Saeki, Tsuguo Iwatani, Atsuko Kitano, Naomi Sakurai, Yuko Tanabe, Chikako Yamauchi, Ataru Igarashi, Yusuke Kajimoto, Sayaka Kuba, Fumikata Hara, Yasuaki Sagara, Sumito Saeki, null null
Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives. Breast cancer (Tokyo, Japan) (2023)
Akina Takami, Masafumi Kato, Hisato Deguchi, Ataru Igarashi
Value elements and methods of value-based pricing for drugs in Japan: a systematic review. Expert review of pharmacoeconomics & outcomes research (2023)
Ataru Igarashi, Yosuke Nakano, Mariko Yoneyama-Hirozane
Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: a conjoint analysis. Expert review of vaccines 21 (2) (2022)
Hiroaki Mamiya, Ataru Igarashi
Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan. Journal of medical economics 25 (1) (2022)
M Müller, Ataru Igarashi, K Hashiguchi, M Kappel, F Paolini, H Yoshisue, M Funakubo, H Sharma, M Okano
The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients. Journal of medical economics 25 (1) (2022)
Ataru Igarashi, Keiko Maruyama-Sakurai, Anna Kubota, Hiroki Akiyama, Toshitaka Yajima, Shun Kohsaka, Hiroaki Miyata
Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan. Diabetes therapy : research, treatment and education of diabetes and related disorders 13 (7) (2022)
Masaru Iwata, Yoshihiro Oikawa, Yutaka Shimizu, Naotaka Sakashita, Ayako Shoji, Ataru Igarashi, Yutaka Osuga
Efficacy of Low-Dose Estrogen-Progestins and Progestins in Japanese Women with Dysmenorrhea: A Systematic Review and Network Meta-analysis. Advances in therapy 39 (11) (2022)
Yuki Hashimoto, Akitoshi Hayashi, Takashi Tonegawa, Lida Teng, Ataru Igarashi
Cost-saving prediction model of transfer to palliative care for terminal cancer patients in a Japanese general hospital. Journal of market access & health policy 10 (1) (2022)
Ataru Igarashi, Emi Hirose, Yasuhiro Kobayashi, Naohiro Yonemoto, Bennett Lee
Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert review of vaccines 21 (5) (2022)
Hiroki Sugimori, Maki Hirao, Ataru Igarashi, Hiroshi Yatsuhashi, Shunya Ikeda, Naohiko Masaki, Hiroshi Yotsuyanagi, Takeshi Yoda, Takeshi Odajima, Tomoyuki Takura, Tomohiro Hirao
Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan. Scientific reports 12 (1) (2022)
Ataru Igarashi, Shunya Ikeda
Value assessment of new interventions for Alzheimer's disease dementia in Japan based on literature review and group interview. Expert review of pharmacoeconomics & outcomes research 22 (8) (2022)
Takaaki Ikeda, Ataru Igarashi, Israel Terungwa Agaku, Masayasu Murakami, Takahiro Tabuchi
Health-Related Quality of Life during COVID-19 Pandemic: Assessing Impacts of Job Loss and Financial Support Programs in Japan. Applied research in quality of life (2021)
Hirokazu Takahashi, Ayako Shoji, Kinya Kokubo, Ataru Igarashi
A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan. Gastroenterology research and practice 2021 (2021)
Rachel Lee-Yin Tan, Zhihao Yang, Ataru Igarashi, Michael Herdman, Nan Luo
How Do Respondents Interpret and View the EQ-VAS? A Qualitative Study of Three Asian Populations. The patient 14 (2) (2021)
Hiroaki Mamiya, Ataru Igarashi
Determinants of market prices for drugs under Japan's national health insurance. Journal of medical economics 24 (1) (2021)
Ataru Igarashi, Rei Goto, Mariko Yoneyama-Hirozane
Willingness to pay for QALY: perspectives and contexts in Japan. Journal of medical economics 22 (10) (2019)

Ataru Igarashi.css-eqlu8i{font-size:small;padding-left:4px;} (A Igarashi)

Publication Activity (10 Years)

Top Topics

Top Venues

Ataru Igarashi (A Igarashi)